Literature DB >> 26097183

A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation.

Aristea Papageorgiou1, Clio P Mavragani1, Andrianos Nezos1, Elias Zintzaras2, Luca Quartuccio3, Salvatore De Vita3, Michael Koutsilieris1, Athanasios G Tzioufas1, Haralampos M Moutsopoulos1, Michael Voulgarelis1.   

Abstract

OBJECTIVE: To study the prevalence, clinical associations, and functional implications of the His159Tyr mutation of the BAFF receptor (BAFF-R) in patients with Sjögren's syndrome (SS).
METHODS: The BAFF-R His159Tyr mutation was evaluated using polymerase chain reaction (PCR)-based assays in 247 patients with SS (of whom 70 had SS complicated by lymphoma [SS-lymphoma]), 145 with systemic lupus erythematosus (SLE), and 101 with rheumatoid arthritis (RA), as well as 180 healthy controls. Real-time PCR and Western blotting were performed for the quantification of both NF-κB1 and NF-κB2 messenger RNA (mRNA) transcript and protein levels in isolated B cells from patients with SS-lymphoma carrying the mutation (SS-lymphoma-BAFF-RHis159Tyr -derived B cells) compared to B cells from patients with SS-lymphoma who were not carriers of the mutation and healthy controls.
RESULTS: Both the SS-lymphoma and SS-nonlymphoma patient subgroups exhibited significantly higher frequencies of the His159Tyr BAFF-R mutation compared to healthy controls (8.6% of SS-lymphoma patients and 6.2% of SS-nonlymphoma patients versus 1.7% of healthy controls; P = 0.02 and P = 0.04, respectively). The corresponding frequencies of the His159Tyr BAFF-R mutation in SLE and RA patients were 3.5% and 3%, respectively. Of interest, 71.4% of the SS patients with mucosa-associated lymphoid tissue (MALT) lymphoma who were between the ages of 31 and 40 years at disease onset were mutation carriers. The generalized odds ratio for the development of SS-related MALT lymphoma in the younger age at onset (age <40 years) group in the presence of the BAFF-R mutation was 6.1 (95% confidence interval 2.0-18.7) (P < 0.01). Expression of NF-κB at both the mRNA and protein level was up-regulated in SS-lymphoma-BAFF-RHis159Tyr -derived B cells.
CONCLUSION: This study identifies an increased prevalence of the BAFF-R His159Tyr mutation in patients with SS, particularly in those with SS complicated by MALT lymphoma whose disease onset occurred at a younger age. BAFF-RHis159Tyr -mediated activation of the alternate NF-κB pathway might contribute to the pathogenesis of SS-related lymphoproliferative disease.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26097183     DOI: 10.1002/art.39231

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  24 in total

1.  Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma.

Authors:  Gaetane Nocturne; Elena Pontarini; Michele Bombardieri; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-03-05       Impact factor: 7.580

2.  Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.

Authors:  Adrianos Nezos; Fotini Gravani; Anna Tassidou; Efstathia K Kapsogeorgou; Michael Voulgarelis; Michael Koutsilieris; Mary K Crow; Clio P Mavragani
Journal:  J Autoimmun       Date:  2015-07-14       Impact factor: 7.094

Review 3.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 4.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

5.  Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of Sjögren's Syndrome Patients.

Authors:  Konstantina D Kourou; Vasileios C Pezoulas; Eleni I Georga; Themis Exarchos; Costas Papaloukas; Michalis Voulgarelis; Andreas Goules; Andrianos Nezos; Athanasios G Tzioufas; Earalampos M Moutsopoulos; Clio Mavragani; Dimitrios I Fotiadis
Journal:  IEEE Open J Eng Med Biol       Date:  2020-02-14

Review 6.  B cells in the pathogenesis of primary Sjögren syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

7.  Uncovering potential single nucleotide polymorphisms, copy number variations and related signaling pathways in primary Sjogren's syndrome.

Authors:  Xuan Qi; Xi-Qin Wang; Lu Jin; Li-Xia Gao; Hui-Fang Guo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Genetics and epigenetics in primary Sjögren's syndrome.

Authors:  Juliana Imgenberg-Kreuz; Astrid Rasmussen; Kathy Sivils; Gunnel Nordmark
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 9.  Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC).

Authors:  Cesare Mazzaro; Luigino Dal Maso; Laura Gragnani; Marcella Visentini; Francesco Saccardo; Davide Filippini; Pietro Andreone; Anna Linda Zignego; Valter Gattei; Giuseppe Monti; Massimo Galli; Luca Quartuccio
Journal:  Viruses       Date:  2021-05-30       Impact factor: 5.048

10.  Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?

Authors:  Adrianos Nezos; Charalampos Skarlis; Anna Psarrou; Konstantinos Markakis; Panagiotis Garantziotis; Asimina Papanikolaou; Fotini Gravani; Michael Voulgarelis; Athanasios G Tzioufas; Michael Koutsilieris; Haralampos M Moutsopoulos; Eleni Kotsifaki; Clio P Mavragani
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.